With more and more targeted drugs clinical applications, such as Epidermal Growth Factor Receptor (EGFR)–Tyrosine Receptor Inhibitors (TKIs), the overall survival time of patients with lung adenocarcinoma, was significantly prolonged.5, 6, 7. This evidence concerns the gene EGFR and lung adenocarcinoma.